C-reactive protein: not always a reliable marker of ongoing cytokine release syndrome in CAR-T therapy following IL-6 blockade.

Chimeric antigen receptor T-cell(CAR-T) therapy is an increasingly utilized treatment modality with FDA approval for relapsed or refractory(R/R) CD19 positive B-cell Acute Lymphoblastic Leukemia(B-...